Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Mult Scler. 2000 Jun;6(3):137-9.

Antinuclear antibodies and response to IFNbeta-1a therapy in relapsing-remitting multiple sclerosis.

Author information

  • 1Department of Neurological Sciences, University of Rome 'La Sapienza', Rome, Italy.


We determined whether positive ANA was related to response to rIFNss-1a in 62 relapsing-remitting MS patients. According to the presence of antinuclear antibodies (ANA) at baseline and during the first 6 months of treatment, patients were sorted in different groups. The clinical and MRI outcome during short-term (6 months) and long-term (24 months) treatment period was not statistically different between the groups. Therefore, the response to IFNbeta-1a seems not to be influenced by ANA occurrence either before or during treatment. When the analysis was extended to other autoantibodies (i. e. antithyroid, anticardiolipin) similar results were obtained.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk